CRBP Stock — Corbus Pharmaceuticals Holding

Corbus Pharmaceuticals Holding (CRBP)

Updated October 16, 2026.

CRBP is a Stock. Total return is -95.0% over the past 12 years, 469.8 points behind SPY at 374.8%.

Corbus Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company developing therapeutics for cancer and obesity, with a pipeline that includes CRB-701, an antibody drug conjugate targeting Nectin-4 for cancer treatment, and CRB-913, a cannabinoid receptor inverse agonist for obesity. The company does not currently have an established distribution schedule. This security appeals to investors seeking exposure to early-stage pharmaceutical development with a higher risk profile and no current income component.

CRBP performance versus SPY

Price and return data through 2026-10-16.

Total return is -95.0% over the past 12 years, 469.8 points behind SPY at 374.8%. Over the past year its total return — price change plus distributions reinvested — is -76.3%. Its deepest 1-year drawdown was 77.6%.

CRBP key facts

Asset type

Stock

Asset class

Equity

Inception date

10/27/2014

Distribution frequency

None

Last close

$4.52 (as of 2026-10-16)

Market cap

$87,422,644

Average volume

1065300.0

Beta

2.632

Payout ratio

0.0%

EPS

$-6.25

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CRBP risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 77.6%.

Who may consider CRBP — and who may not

It is a weaker fit for investors who need monthly cash flow (CRBP does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CRBP

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions